Research
Hormonal
SGLT2 inhibitors and GLP-1 receptor agonists reduce arrhythmia risk in diabetic patients by ameliorating intracellular sodium and calcium dysregulation and reducing fibrosis.
If you have type 2 diabetes, ask your doctor about SGLT2 inhibitors or GLP-1 agonists. These drugs do more than lower blood sugar; they help stabilize the electrical activity of your heart and reduce scarring, lowering your risk of sudden cardiac death.
GoodSupportsHIGH confidence
SGLT2 inhibitors may ameliorate intracellular sodium and calcium dysregulation in addition to reducing fibrosis, cardiomyopathy, and inflammation, thereby reducing pro-arrhythmia in the setting of metabolic disorders through various mechanimsm.
Why this rating
Based on clinical recommendations and mechanistic studies cited in the review.
Source
Sudden Cardiac Death in Diabetes and Obesity: Mechanisms and Therapeutic Strategies
Carol Ann Remme · Canadian Journal of Cardiology · 2022
DOI 10.1016/j.cjca.2022.01.001
narrative_reviewCited 48×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weight loss interventions, including bariatric surgery and dietary changes, reduce the risk of ventricular arrhythmias and sudden cardiac death in obese patients by correcting electrophysiological abnormalities.Good
- Branched-chain amino acid (BCAA) dysregulation directly causes pro-arrhythmic effects, including action potential prolongation and calcium dysregulation, independent of structural cardiac changes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →